核裂变反应可以释放大量能量，伴随着中子和γ光子，产生混合辐射场，使核反应堆中发生一系列反应。这项研究展示了一种在不使用放射性前体和还原剂的情况下合成放射性金纳米粒子（RGNP）的一锅/一步方法。三价金离子被还原成金纳米颗粒（8.6-146 nm），并且197Au原子的特定部分同时转化为198Au原子，使纳米颗粒具有放射性。我们认为，为了推进癌症治疗的纳米技术的发展，利用核能来制备金纳米颗粒是可行的。通过对流增强递送 (CED) 和口服替莫唑胺 (TMZ) 联合应用 RGNP，在治疗患有胶质母细胞瘤的小鼠中显示出协同效应。与单独 RGNP（38.4 ± 2.2 天）或 TMZ（42.8 ± 2.5 天）治疗相比，RGNP/TMZ 治疗的平均生存期为 68.9 ± 9.7 天。基于生物发光图像、正电子发射断层扫描和免疫组织化学检查的验证，联合治疗可以抑制胶质母细胞瘤的增殖，凸显了RGNP和TMZ同步放化疗（CCRT）的利基市场。

Nuclear fission reactions can release massive amounts of energy accompanied by neutrons and γ photons, which create a mixed radiation field and enable a series of reactions in nuclear reactors. This study demonstrates a one-pot/one-step approach to synthesizing radioactive gold nanoparticles (RGNP) without using radioactive precursors and reducing agents. Trivalent gold ions are reduced into gold nanoparticles (8.6-146 nm), and a particular portion of 197Au atoms is simultaneously converted to 198Au atoms, rendering the nanoparticles radioactive. We suggest that harnessing nuclear energy to gold nanoparticles is feasible in the interests of advancing nanotechnology for cancer therapy. A combination of RGNP applied through convection-enhanced delivery (CED) and temozolomide (TMZ) through oral administration demonstrates the synergistic effect in treating glioblastoma-bearing mice. The mean survival for RGNP/TMZ treatment was 68.9 ± 9.7 days compared to that for standalone RGNP (38.4 ± 2.2 days) or TMZ (42.8 ± 2.5 days) therapies. Based on the verification of bioluminescence images, positron emission tomography, and immunohistochemistry inspection, the combination treatment can inhibit the proliferation of glioblastoma, highlighting the niche of concurrent chemoradiotherapy (CCRT) attributed to RGNP and TMZ.